Search Results

Baylor Genetics today announced the availability of a new RNA sequencing test, RNAseq, for Whole Exome and Whole Genome Sequencing (WES/WGS).

Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, will showcase its latest advancements and research discoveries at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting on March 12-16 in Toronto, Canada.

Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, continued to accelerate its market leadership and growth over the last 12 months, expanding its test menu, commercial reach, lab operations, technology, and customer experience initiatives.

Baylor Genetics announced its scientists and genetic counselors will present 10 research abstracts at three major upcoming conferences, including the National Organization for Rare Disorders Breakthrough Summit, National Society of Genetic Counselors Annual Conference, and the American Society of Human Genetics Annual Meeting.

Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing and precision medicine, announced the availability of a Neuromuscular Disorders Panel.

Baylor Genetics announced the availability of a new Neurodevelopmental Disorders Panel for children and other patients affected by a suspected or clinically diagnosed autism spectrum disorder, intellectual disability, and/or developmental delay.

Olink Holding AB announced that the Baylor College of Medicine Human Genome Sequencing Center has selected the Olink Explore platform as a proteomics component of their world-class multiomics offering.

Astellas is opening a second location of Universal Cells, its wholly owned subsidiary, at a research campus in Japan and transferring 12 roles from Universal’s Seattle location.

Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.